Search

Your search keyword '"Su, Li"' showing total 418 results
Start Over Author "Su, Li" Publisher wiley

Refine your results

more »

more »

418 results on '"Su, Li"'

1. Prognostic utility of preoperative inflammatory markers in patients with intrahepatic cholangiocarcinoma after hepatic resection: A systematic review and meta‐analysis

Author

Hongxia Cui, Yarong Li, Su Li, and Guangxuan Liu

Subjects
inflammatory biomarkers, intrahepatic cholangiocarcinoma, meta‐analysis, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The prognostic value of preoperative systemic inflammatory markers, including the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR), remains controversial in patients with intrahepatic cholangiocarcinoma (ICC). Therefore, this meta‐analysis aimed to investigate the prognostic value of preoperative NLR, PLR, and LMR in patients with ICC who underwent hepatic resection. Methods We conducted a comprehensive search of four electronic databases. Two researchers assessed the quality of the available data using the Newcastle–Ottawa Scale. We selected overall survival (OS) as the primary outcome and recurrence‐free survival (RFS) and disease‐free survival (DFS) as secondary outcomes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were merged to evaluate the associations between inflammatory markers and ICC patient prognosis. Results Fifteen studies (18 cohorts) with 4123 cases were included in this meta‐analysis. The results revealed that a high preoperative NLR was associated with short OS and RFS (HR = 1.04, 95% CI: 1.01–1.07, and HR = 1.29, 95% CI: 1.04–1.60, respectively) in patients with ICC. However, the association between PLR or LMR and ICC prognosis was not statistically significant. In addition, the publication bias and sensitivity analyses demonstrated that the results were reliable and stable. Conclusion Our meta‐analysis revealed that preoperative NLR may be a useful prognostic predictor for patients with ICC.

Published
2023
Full Text
View/download PDF

4. Soybean steroids improve crop abiotic stress tolerance and increase yield

Author

Yu, Tai‐Fei, primary, Hou, Ze‐Hao, additional, Wang, Hai‐Long, additional, Chang, Shi‐Yang, additional, Song, Xin‐Yuan, additional, Zheng, Wei‐Jun, additional, Zheng, Lei, additional, Wei, Ji‐Tong, additional, Lu, Zhi‐Wei, additional, Chen, Jun, additional, Zhou, Yong‐Bin, additional, Chen, Ming, additional, Sun, Su‐Li, additional, Jiang, Qi‐Yan, additional, Jin, Long‐Guo, additional, Ma, You‐Zhi, additional, and Xu, Zhao‐Shi, additional

Published
2024
Full Text
View/download PDF

6. Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle

Author

Su Li, Zhouyu Lu, Yue Huang, Yin Wang, Qiao Jin, Xingchao Shentu, Juan Ye, Jian Ji, Ke Yao, and Haijie Han

Subjects
anti‐inflammation, anti‐oxidant stress, dry eye, micelles, vicious cycle, Science
Abstract

Abstract Dry eye disease (DED) impacts ≈30% of the world's population and causes serious ocular discomfort and even visual impairment. Inflammation is one core cause of the DED vicious cycle, a multifactorial deterioration in DED process. However, there are also reactive oxygen species (ROS) regulating inflammation and other points in the cycle from the upstream, leading to treatment failure of current therapies merely targeting inflammation. Accordingly, the authors develop micelle‐based eye drops (more specifically p38 mitogen‐activated protein kinases (MAPK) inhibitor Losmapimod (Los)‐loaded and ROS scavenger Tempo (Tem)‐conjugated cationic polypeptide micelles, designated as MTem/Los) for safe and efficient DED management. Cationic MTem/Los improve ocular retention of conjugated water‐soluble Tem and loaded water‐insoluble Los via electrostatic interaction with negatively charged mucin on the cornea, enabling an increase in therapeutic efficiency and a decrease in dosing frequency. Mechanistically, MTem/Los effectively decrease ROS over‐production, reduce the expression of proinflammatory cytokines and chemokines, restrain macrophage proinflammatory phenotypic transformation, and inhibit cell apoptosis. Therapeutically, the dual‐functional MTem/Los suppress the inflammatory response, reverse corneal epithelial defect, save goblet cell dysfunction, and recover tear secretion, thus breaking the vicious cycle and alleviating the DED. Moreover, MTem/Los exhibit excellent biocompatibility and tolerability for potential application as a simple and rapid treatment of oxidative stress‐ and inflammation‐induced disorders, including DED.

Published
2022
Full Text
View/download PDF

7. Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis

Author

Kai Wang, Li Jiang, Yueyang Zhong, Yin Zhang, Qichuan Yin, Su Li, Xiaobo Zhang, Haijie Han, and Ke Yao

Subjects
corneal alkali burn, corneal neovascularization, ferroptosis, ferrostatin‐1, liposome, Chemical engineering, TP155-156, Biotechnology, TP248.13-248.65, Therapeutics. Pharmacology, RM1-950
Abstract

Abstract Alkali burn is a potentially blinding corneal injury. During the progression of alkali burn‐induced injury, overwhelmed oxidative stress in the cornea triggers cell damage, including oxidative changes in cellular macromolecules and lipid peroxidation in membranes, leading to impaired corneal transparency, decreased vision, or even blindness. In this study, we identified that ferroptosis, a type of lipid peroxidation‐dependent cell death, mediated alkali burn‐induced corneal injury. Ferroptosis‐targeting therapy protected the cornea from cell damage and neovascularization. However, the specific ferroptosis inhibitor ferrostatin‐1 (Fer‐1) is hydrophobic and cannot be directly applied in the clinic. Therefore, we developed Fer‐1‐loaded liposomes (Fer‐1‐NPs) to improve the bioavailability of Fer‐1. Our study demonstrated that Fer‐1‐NPs exerted remarkable curative effects regarding corneal opacity and neovascularization in vivo. The efficacy was comparable to that of dexamethasone, but without appreciable side effects. The significant suppression of ferroptosis (induced by lipid peroxidation and mitochondria disruption), inflammation, and neovascularization might be the mechanisms underlying the therapeutic effect of Fer‐1‐NPs. Moreover, the Fer‐1‐NPs treatment showed no signs of cytotoxicity, hematologic toxicity, or visceral organ damage, which further confirmed the biocompatibility. Overall, Fer‐1‐NPs provide a new prospect for safe and effective therapy for corneal alkali burn.

Published
2022
Full Text
View/download PDF

10. Brain age gap, dementia risk factors and cognition in middle age

Author

Stefaniak, James D, primary, Mak, Elijah, additional, Su, Li, additional, Carter, Stephen F, additional, Dounavi, Maria‐Eleni, additional, Muniz‐Terrera, Graciela, additional, Wells, Katie, additional, Ritchie, Karen, additional, Lawlor, Brian, additional, Naci, Lorina, additional, Koychev, Ivan, additional, Malhotra, Paresh A, additional, Ritchie, Craig W, additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

12. Investigating the impact of APOE4 genotype on the association between cerebral blood flow and haematological properties in mid‐life adults

Author

Dounavi, Maria‐Eleni, primary, Mak, Elijah, additional, Low, Audrey, additional, Williams, Guy B, additional, Wells, Katie, additional, Muniz‐Terrera, Graciela, additional, Lawlor, Brian A, additional, Naci, Lorina, additional, Malhotra, Paresh A, additional, Koychev, Ivan, additional, Ritchie, Karen, additional, Su, Li, additional, Ritchie, Craig W, additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

14. Multi‐modal MR and synaptic PET changes in dementia with Lewy bodies

Author

Mak, Elijah, primary, Carter, Stephen F, additional, Savulich, George, additional, Holland, Negin, additional, Swann, Peter, additional, McKiernan, Elizabeth, additional, Chouliaras, Leonidas, additional, Malpetti, Maura, additional, Su, Li, additional, Jones, P Simon, additional, Rowe, James B., additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

15. Apoe ε4 exacerbates age‐dependent decline of cortical microstructural changes in cognitively normal midlife individuals: the PREVENT‐Dementia and ALFA studies

Author

Mak, Elijah, primary, Dounavi, Maria‐Eleni, additional, Operto, Grégory, additional, Ziukelis, Elina T, additional, Jones, P Simon, additional, Low, Audrey, additional, Swann, Peter, additional, Newton, Coco, additional, Muniz‐Terrera, Graciela, additional, Malhotra, Paresh A, additional, Koychev, Ivan, additional, Falcon, Carles, additional, Mackay, Clare, additional, Lawlor, Brian, additional, Naci, Lorina, additional, Wells, Katie, additional, Ritchie, Craig W, additional, Ritchie, Karen, additional, Su, Li, additional, Gispert, Juan Domingo, additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

16. DNA methylation alterations in Lewy Body Dementia

Author

Chouliaras, Leonidas, primary, Thomas, Alan J, additional, Clark, Graeme, additional, Donaghy, Paul C, additional, Swann, Peter, additional, Malpetti, Maura, additional, Mak, Elijah, additional, Savulich, George, additional, Prats‐Sedano, Maria A, additional, Low, Audrey, additional, Su, Li, additional, Rowe, James B., additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

17. Inflammation blood profiles across neurodegenerative diseases

Author

Malpetti, Maura, primary, Swann, Peter, additional, Chouliaras, Leonidas, additional, Ashton, Nicholas J., additional, Tsvetanov, Kamen A, additional, Street, Duncan, additional, Whiteside, David J, additional, Cope, Thomas E, additional, Savulich, George, additional, Rittman, Timothy, additional, Surendranathan, Ajenthan, additional, Murley, Alexander G, additional, Stockton, Katherine, additional, Bevan‐Jones, W Richard, additional, Prats‐Sedano, Maria A, additional, Su, Li, additional, O'Brien, John T, additional, and Rowe, James B., additional

Published
2023
Full Text
View/download PDF

18. Cerebral microbleeds in traumatic brain injury associated with differential risk factors and clinical outcomes: the PREVENT‐Dementia study

Author

Low, Audrey, primary, McKiernan, Elizabeth, additional, Prats‐Sedano, Maria A, additional, Carter, Stephen F, additional, Stefaniak, James D, additional, Su, Li, additional, Dounavi, Maria‐Eleni, additional, Muniz‐Terrera, Graciela, additional, Jenkins, Natalie D, additional, Ritchie, Karen, additional, Lawlor, Brian, additional, Naci, Lorina, additional, Malhotra, Paresh A, additional, Thayanandan, Tony, additional, Mackay, Clare, additional, Koychev, Ivan, additional, Raymont, Vanessa, additional, Ritchie, Craig W, additional, and O'Brien, John T, additional

Published
2023
Full Text
View/download PDF

22. A Ubiquitin‐Dependent Switch on MEF2D Senses Pro‐Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer

Author

Xiang, Junyu, primary, Zhang, Ni, additional, Du, Aibei, additional, Li, Jinyang, additional, Luo, Mengyun, additional, Wang, Yuzhu, additional, Liu, Meng, additional, Yang, Luming, additional, Li, Xianfeng, additional, Wang, Lin, additional, Liu, Qin, additional, Chen, Dongfeng, additional, Wang, Tao, additional, Bian, Xiu‐wu, additional, Qin, Zhong‐yi, additional, Su, Li, additional, Wen, Liangzhi, additional, and Wang, Bin, additional

Published
2023
Full Text
View/download PDF

23. Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer

Author

Zhonghan Zhang, Yang Zhang, Fan Luo, Yuxiang Ma, Wenfeng Fang, Jing Zhan, Su Li, Yunpeng Yang, Yuanyuan Zhao, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Shen Zhao, Yan Huang, Hongyun Zhao, and Li Zhang

Subjects
antiangiogenic therapy, Apatinib, EGFR‐TKIs, Gefitinib, NSCLC, Medicine (General), R5-920
Abstract

Abstract Background Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally effective VEGFR‐2 tyrosine kinase inhibitor (TKI). This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and antitumor activity of apatinib plus gefitinib as a therapy for EGFR‐mutant advanced NSCLC. Methods Advanced non‐squamous NSCLC participants harbored with the EGFR 19 deletion or the 21 L858R point mutation were included. There were two cohorts: Cohort A: apatinib 500 mg + gefitinib 250 mg. Cohort B: apatinib 250 mg + gefitinib 250 mg. The primary endpoint was safety profile. Other endpoints consisted of PK analysis, objective response rate (ORR), and progression‐free survival (PFS). Exploratory analysis was conducted using next‐generation sequencing of plasma circulating‐tumor DNA. Results Between July 2016 and April 2017, 13 of NSCLC patients were recruited. Six patients were pooled in Cohort A, while seven patients were in Cohort B. Adverse events (AEs) were tolerable (mostly grade 1–2) and the treatment‐related AEs were similar in both cohorts: rash (100% vs 71.4%), diarrhea (66.7% vs 71.4%), hypertension (66.7% vs 71.4%), proteinuria (66.7% vs 42.9%), and hand‐foot skin reaction (33.3% vs 28.6%). The area under plasma concentration‐time curve for the steady state of apatinib was 2864.73 ± 2605.54 ng mL–1 h–1 in Cohort A and 2445.09 ± 1550.89 ng mL–1 h–1 in Cohort B. Of the 11 patients evaluable for efficacy, Cohort A achieved an ORR of 80.0% and reached a median PFS of 19.2 months, while it was 83.3% and 13.4 months in Cohort B. Patients without a concomitant mutation at baseline had a prolonged PFS tendency (20.99 months v 13.21 months, P = .0624). The EGFR‐T790M mutation remained the dominant resistance mechanism. Conclusion Apatinib (500 mg) plus gefitinib (250 mg) showed a tolerable safety profile and encouraging antitumor activity for advanced EGFR‐mutant NSCLC in the first‐line setting. Phase III trials of apatinib (500 mg) plus gefitinib (250 mg) are warranted. Trial registration Clinicaltrials.gov, NCT02824458, date of registration June 23, 2016.

Published
2020
Full Text
View/download PDF

26. <scp> CELSR1 </scp> variants are associated with partial epilepsy of childhood

Author

Zheng, Chen, Sheng, Luo, Zhi-Gang, Liu, Yan-Chun, Deng, Su-Li, He, Xiao-Rong, Liu, Yong-Hong, Yi, Jie, Wang, Liang-Di, Gao, Bing-Mei, Li, Zhi-Jun, Wu, Zi-Long, Ye, De-Hai, Liang, Wen-Jun, Bian, and Wei-Ping, Liao

Subjects
Heterozygote, Cellular and Molecular Neuroscience, Psychiatry and Mental health, Mutation, Missense, Humans, Epilepsies, Partial, Cadherins, Alleles, Genetics (clinical)
Abstract

CELSR1 gene, encoding cadherin EGF LAG seven-pass G-type receptor 1, is mainly expressed in neural stem cells during the embryonic period. It plays an important role in neurodevelopment. However, the relationship between CELSR1 and disease of the central nervous system has not been defined. In this study, we performed trios-based whole-exome sequencing in a cohort of 356 unrelated cases with partial epilepsy without acquired causes and identified CELSR1 variants in six unrelated cases. The variants included one de novo heterozygous nonsense variant, one de novo heterozygous missense variant, and four compound heterozygous missense variants that had one variant was located in the extracellular region and the other in the cytoplasm. The patients with biallelic variants presented severe epileptic phenotypes, whereas those with heterozygous variants were associated with a mild epileptic phenotype of benign epilepsy with centrotemporal spikes (BECTS). These variants had no or low allele frequency in the gnomAD database. The frequencies of the CELSR1 variants in this cohort were significantly higher than those in the control populations. The evidence from ClinGen Clinical-Validity Framework suggested a strong association between CELSR1 variants and epilepsy. These findings provide evidence that CELSR1 is potentially a candidate pathogenic gene of partial epilepsy of childhood.

Published
2022
Full Text
View/download PDF

27. Prognostic utility of preoperative inflammatory markers in patients with intrahepatic cholangiocarcinoma after hepatic resection: A systematic review and meta‐analysis

Author

Hongxia Cui, Yarong Li, Su Li, and Guangxuan Liu

Subjects
Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging
Abstract

The prognostic value of preoperative systemic inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), remains controversial in patients with intrahepatic cholangiocarcinoma (ICC). Therefore, this meta-analysis aimed to investigate the prognostic value of preoperative NLR, PLR, and LMR in patients with ICC who underwent hepatic resection.We conducted a comprehensive search of four electronic databases. Two researchers assessed the quality of the available data using the Newcastle-Ottawa Scale. We selected overall survival (OS) as the primary outcome and recurrence-free survival (RFS) and disease-free survival (DFS) as secondary outcomes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were merged to evaluate the associations between inflammatory markers and ICC patient prognosis.Fifteen studies (18 cohorts) with 4123 cases were included in this meta-analysis. The results revealed that a high preoperative NLR was associated with short OS and RFS (HR = 1.04, 95% CI: 1.01-1.07, and HR = 1.29, 95% CI: 1.04-1.60, respectively) in patients with ICC. However, the association between PLR or LMR and ICC prognosis was not statistically significant. In addition, the publication bias and sensitivity analyses demonstrated that the results were reliable and stable.Our meta-analysis revealed that preoperative NLR may be a useful prognostic predictor for patients with ICC.

Published
2022
Full Text
View/download PDF

28. A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease

Author

Payne, Thomas, primary, Appleby, Matthew, additional, Buckley, Ellen, additional, van Gelder, Linda M.A., additional, Mullish, Benjamin H., additional, Sassani, Matilde, additional, Dunning, Mark J., additional, Hernandez, Dena, additional, Scholz, Sonja W., additional, McNeill, Alisdair, additional, Libri, Vincenzo, additional, Moll, Sarah, additional, Marchesi, Julian R., additional, Taylor, Rosie, additional, Su, Li, additional, Mazzà, Claudia, additional, Jenkins, Thomas M., additional, Foltynie, Thomas, additional, and Bandmann, Oliver, additional

Published
2023
Full Text
View/download PDF

29. Selenium nanoparticles improve nickel‐induced testosterone synthesis disturbance by down‐regulating miR ‐708‐5p/p38 MAPK pathway in Leydig cells

Author

Wang, Shuang, primary, Gu, Xueyan, additional, Ma, Jianhua, additional, Gu, Zhangyu, additional, Zhang, Rui, additional, Li, Ruifen, additional, Bai, Jun, additional, Li, Peng, additional, Wei, Linyu, additional, Ye, Yixing, additional, Wang, Yan, additional, Zhang, Li, additional, Su, Li, additional, and Liang, Changhao, additional

Published
2023
Full Text
View/download PDF

33. A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease

Author

Payne, Thomas, Appleby, Matthew, Buckley, Ellen, van Gelder, Linda MA, Mullish, Benjamin H, Sassani, Matilde, Dunning, Mark J, Hernandez, Dena, Scholz, Sonja W, McNeill, Alisdair, Libri, Vincenzo, Moll, Sarah, Marchesi, Julian R, Taylor, Rosie, Su, Li, Mazzà, Claudia, Jenkins, Thomas M, Foltynie, Thomas, Bandmann, Oliver, Mullish, Benjamin H [0000-0001-6300-3100], Scholz, Sonja W [0000-0002-6623-0429], Foltynie, Thomas [0000-0003-0752-1813], Bandmann, Oliver [0000-0003-3149-0252], and Apollo - University of Cambridge Repository

Subjects
31P-MR spectroscopy, supervised gait analysis, neuroprotection, UDCA, ursodeoxycholic acid
Abstract

BACKGROUND: Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across a range of preclinical in vitro and in vivo models of PD. OBJECTIVES: To investigate the safety and tolerability of high-dose UDCA in PD and determine midbrain target engagement. METHODS: The UP (UDCA in PD) study was a phase II, randomized, double-blind, placebo-controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The primary outcome was safety and tolerability. Secondary outcomes included 31-phosphorus magnetic resonance spectroscopy (31 P-MRS) to explore target engagement of UDCA in PD midbrain and assessment of motor progression, applying both the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) and objective, motion sensor-based quantification of gait impairment. RESULTS: UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain 31 P-MRS demonstrated an increase in both Gibbs free energy and inorganic phosphate levels in the UDCA treatment group compared to placebo, reflecting improved ATP hydrolysis. Sensor-based gait analysis indicated a possible improvement of cadence (steps per minute) and other gait parameters in the UDCA group compared to placebo. In contrast, subjective assessment applying the MDS-UPDRS-III failed to detect a difference between treatment groups. CONCLUSIONS: High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Published
2023

41. A trans‐omics assessment of gene–gene interaction in early‐stage NSCLC

Author

Chen, Jiajin, primary, Song, Yunjie, additional, Li, Yi, additional, Wei, Yongyue, additional, Shen, Sipeng, additional, Zhao, Yang, additional, You, Dongfang, additional, Su, Li, additional, Bjaanæs, Maria Moksnes, additional, Karlsson, Anna, additional, Planck, Maria, additional, Staaf, Johan, additional, Helland, Åslaug, additional, Esteller, Manel, additional, Shen, Hongbing, additional, Christiani, David C., additional, Zhang, Ruyang, additional, and Chen, Feng, additional

Published
2022
Full Text
View/download PDF

42. Multifactor mid‐life risk for Alzheimer’s disease associated with alterations in navigation but not episodic memory: the PREVENT‐Dementia study

Author

Newton, Coco, primary, Pope, Marianna, additional, Dounavi, Maria‐Eleni, additional, Carter, Stephen F, additional, Muniz‐Terrera, Graciela, additional, Henson, Richard N, additional, Ritchie, Karen, additional, Ritchie, Craig W., additional, O'Brien, John T, additional, Su, Li, additional, and Chan, Dennis, additional

Published
2022
Full Text
View/download PDF

43. Poster Presentations

Author

N. Sutamam, Florent Ginhoux, Barnaby Edward Young, Akshamal M. Gamage, Karen Donceras Nadua, Pavanish Kumar, Chee Fu Yung, Natalie Woon Hui Tan, Amanda Jin Mei Lim, D. Guo, Cheng Tung Chong, K. S. Yeo, Su Li Poh, Jiahui Li, Jing Yao Leong, Randy Foo, Katherine Nay Yaung, Xiao Qian Ng, Joo Guan Yeo, David C. Lye, Camillus Chua, Sharifah Nur Hazirah, Martin Qui, Jerry Kok Yen Chan, Martin Wasser, Lin-Fa Wang, Thaschawee Arkachaisri, Kai Qian Kam, Koh Cheng Thoon, Danielle E. Anderson, Salvatore Albani, L. Ramakrishna, and Shi Huan Tay

Subjects
biology, business.industry, FOXP3, Human leukocyte antigen, CXCR3, Immune system, Rheumatology, TIGIT, Immunology, biology.protein, Medicine, IL-2 receptor, Antibody, business, CD8
Abstract

Background/Purpose: The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in significant mortality, social disorder and economic hardships. We set out to understand why certain individuals could resolve the disease successfully without serious complications by immune profiling of PBMCs from convalescent COVID-19 patients (n = 14) with mild disease trajectory. Methods: We designed 7 peptides targeting the receptor binding region (RBD) of the spike protein of SARS-CoV-2, that encompass broad HLA class I / II alleles, with the aid of the Immune Epitope Database and Analysis Resource (IEDB) website. The RBD site was chosen as it was shown to be protective when neutralising antibodies against this region could negate binding of viral spike protein to host cell ACE-2 receptor. Convalescent COVID-19 patients enrolled in this study were screened and selected for positive antibody titre against the RBD region. PBMCs from convalescent COVID-19 patients were stimulated with/without the peptides for 72hrs and immune profiled (n = 70 markers across two panels) with the high dimensional single cell mass cytometry platform (CyToF). Results: Convalescent COVID-19 patients elicited a robust recall memory T follicular helper response (CD3 + CD4 + CD45RO + CXCR5 + Tigit + ;∗∗∗∗ p < 0.0001) demonstrating peptide efficacy. Unsupervised clustering (FlowSOM) of the CD4 T cell immune landscape reaffirmed increase in memory T follicular subsets and additionally CD4 + CD45RO + CXCR5 -subsets. Further gating of antigen specific memory cells (CD45RO + CD69 + ) revealed an increase in Tbet + CXCR3 + T effectors in both CD4 and CD8 compartments. Strikingly we detected a parallel increase in CD4 + Treg (CD25 + FoxP3 + ) CXCR3 + Tbet + CD45RO + CD152 + Tigit + expression. Conclusions: COVID-19 patients that successfully resolve the viral infection not only mount a robust T effector and follicular response but also in tandem a similar T regulatory profile.

Published
2021
Full Text
View/download PDF

44. The importance of the <scp>IL</scp> ‐1 family of cytokines in nanoimmunosafety and nanotoxicology

Author

Guofang Zhang, Wenhe Luo, Wenjie Yang, Su Li, Dongjie Li, Yanqiao Zeng, and Yang Li

Subjects
Nanomedicine, Interleukins, Interleukin-18, Biomedical Engineering, Humans, Medicine (miscellaneous), Biological Transport, Bioengineering, Interleukin-33, Nanostructures
Abstract

Engineered nanomaterials (ENMs) to which humans are exposed intentionally as nanomedicines or unintentionally as invaders, may elicit unforeseen immune reactions. An uncontrollable ENM-induced immune response poses a potential danger to the human body. During an immunological reaction, interleukin (IL)-1 family cytokines, which play key roles under both physiological and pathological conditions, can be secreted by various types of cells into the surrounding environment to induce a series of defensive reactions. However, the crucial roles played by IL-1 family cytokines in ENM-induced immunological responses have not attracted enough attention from researchers to date. In this review, ENM-mediated inflammatory responses and immunotoxicity are discussed, with the main focus directed to IL-1 family cytokines, including IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36, IL-37, and IL-38. The potential molecular mechanisms of IL-1 family cytokine activity triggered by ENMs, particularly the activation of IL-1α, IL-1β, IL-18, and IL-33, are also reviewed. The understanding of IL-1 family cytokines on nanoimmunosafety provides a fundamental basis for designing safe ENMs that can potentially be used for nanomedicine. This article is categorized under: Toxicology and Regulatory Issues in NanomedicineToxicology of Nanomaterials.

Published
2022
Full Text
View/download PDF

46. Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody

Author

Lin, Chih‐Yen, primary, Wang, Wen‐Hung, additional, Li, Meng‐Chi, additional, Lin, Yu‐Ting, additional, Yang, Zih‐Syuan, additional, Urbina, Aspiro Nayim, additional, Assavalapsakul, Wanchai, additional, Thitithanyanont, Arunee, additional, Chen, Kai‐Ren, additional, Kuo, Chien‐Cheng, additional, Lin, Yu‐Xen, additional, Hsiao, Hui‐Hua, additional, Lin, Kun‐Der, additional, Lin, Shang‐Yi, additional, Chen, Yen‐Hsu, additional, Yu, Ming‐Lung, additional, Su, Li‐Chen, additional, and Wang, Sheng‐Fan, additional

Published
2022
Full Text
View/download PDF

50. Tonsillar Microbiome‐Derived Lantibiotics Induce Structural Changes of IL‐6 and IL‐21 Receptors and Modulate Host Immunity

Author

Li, Jing, primary, Jin, Jiayang, additional, Li, Shenghui, additional, Zhong, Yan, additional, Jin, Yuebo, additional, Zhang, Xuan, additional, Xia, Binbin, additional, Zhu, Yinhua, additional, Guo, Ruochun, additional, Sun, Xiaolin, additional, Guo, Jianping, additional, Hu, Fanlei, additional, Xiao, Wenjing, additional, Huang, Fei, additional, Ye, Hua, additional, Li, Ru, additional, Zhou, Yunshan, additional, Xiang, Xiaohong, additional, Yao, Haihong, additional, Yan, Qiulong, additional, Su, Li, additional, Wu, Lijun, additional, Luo, Tuoping, additional, Liu, Yudong, additional, Guo, Xiaohuan, additional, Qin, Junjie, additional, Qi, Hai, additional, He, Jing, additional, Wang, Jun, additional, and Li, Zhanguo, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results